FIELD: biotechnology and medicine.
SUBSTANCE: invention relates to a method of producing a bioactive kidney cell (BKC), including a genetic modification in the beta-2 microglobulin (B2M) gene to provide a regenerative effect on a natural kidney for the treatment of chronic renal failure.
EFFECT: invention makes it possible to obtain a population of “universal donor” immunologically privileged kidney cells, to which gene editing was applied to obtain a population of modified allogeneic kidney cells administered to patients without the use of immunosuppression.
44 cl, 16 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING CELL VESICLES AND USE THEREOF | 2019 |
|
RU2824136C2 |
| PHARMACEUTICAL FORMULATION DELIVERY DEVICE | 2021 |
|
RU2839077C1 |
| TREATING KIDNEY DISEASE IN SUBJECTS WITH RENAL AND/OR URINARY TRACT ABNORMALITIES | 2020 |
|
RU2823980C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| METHODS OF PRODUCING CELLS EXPRESSING RECOMBINANT RECEPTOR AND RELATED COMPOSITIONS | 2019 |
|
RU2835579C2 |
| CRISPR/CAS PLATFORM FOR EXCLUSIVE SCREENING FOR DETECTING GENETIC VULNERABILITIES ASSOCIATED WITH TAU PROTEIN AGGREGATION | 2020 |
|
RU2808829C2 |
| CRISPR/CAS SCREENING PLATFORM FOR IDENTIFICATION OF GENETIC MODIFIERS OF SEEDING OR AGGREGATION OF TAU PROTEIN | 2020 |
|
RU2819350C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| ENHANCEMENT OF TISSUE-SPECIFIC GENE DELIVERY BY CAPSID MODIFICATION | 2019 |
|
RU2801217C2 |
| ARTIFICIALLY CREATED SC FUNCTION CONTROL SYSTEM | 2017 |
|
RU2768043C2 |
